Interaction Between Diabetes Mellitus and Platelet Reactivity in Determining Long-Term Outcomes Following Percutaneous Coronary Intervention.
Fabio MangiacapraEdoardo BressiIginio ColaioriElisabetta RicottiniIlaria CavallariMarialessia CapuanoMichele Matia ViscusiSilvia SpotoEmanuele BarbatoGermano Di SciascioPublished in: Journal of cardiovascular translational research (2019)
Diabetes mellitus (DM) is an independent predictor of adverse outcomes in patients with coronary artery disease (CAD). We investigated the interaction between DM and high platelet reactivity (HPR) in determining long-term clinical outcomes after percutaneous coronary intervention (PCI). We enrolled 500 patients who were divided based on the presence of DM and HPR. Primary endpoint was the occurrence of major adverse clinical events (MACE) at 5 years. Patients with both DM and HPR showed the highest estimates of MACE (37.9%, log-rank p < 0.001), all-cause death (15.5%, log-rank p = 0.022), and non-fatal myocardial infarction (25.9%, log-rank p < 0.001). At Cox proportional hazard analysis, the coexistence of DM and HPR was an independent predictor of MACE (HR 3.46, 95% CI 1.67-6.06, p < 0.001). Among patients with stable CAD undergoing elective PCI and treated with aspirin and clopidogrel, the combination of DM and HPR identifies a cohort of patients with the highest risk of MACE at 5 years.
Keyphrases
- percutaneous coronary intervention
- coronary artery disease
- antiplatelet therapy
- acute coronary syndrome
- st segment elevation myocardial infarction
- glycemic control
- acute myocardial infarction
- st elevation myocardial infarction
- coronary artery bypass grafting
- atrial fibrillation
- cardiovascular events
- type diabetes
- coronary artery bypass
- risk assessment
- left ventricular
- patients undergoing
- heart failure
- gene expression
- dna methylation
- cardiovascular disease
- newly diagnosed
- skeletal muscle
- drug induced
- data analysis